3D Medicines (HKSE:01244) Retained Earnings : HK$-4,551.0 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. 3D Medicines's retained earnings for the quarter that ended in Dec. 2023 was HK$-4,551.0 Mil.

3D Medicines's quarterly retained earnings declined from Dec. 2022 (HK$-4,060.5 Mil) to Jun. 2023 (HK$-4,172.3 Mil) and declined from Jun. 2023 (HK$-4,172.3 Mil) to Dec. 2023 (HK$-4,551.0 Mil).

3D Medicines's annual retained earnings declined from Dec. 2021 (HK$-2,740.4 Mil) to Dec. 2022 (HK$-4,060.5 Mil) and declined from Dec. 2022 (HK$-4,060.5 Mil) to Dec. 2023 (HK$-4,551.0 Mil).

3D Medicines Retained Earnings Historical Data

The historical data trend for 3D Medicines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Retained Earnings Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-1,505.32

-2,740.41

-4,060.46

-4,550.97

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Retained Earnings	Get a 7-Day Free Trial			-2,740.41	-	-4,060.46	-4,172.29	-4,550.97

3D Medicines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

3D Medicines (HKSE:01244) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines